← ANALYST RATINGS · TIPRANKS

GRAIL Inc (GRAL): analyst forecast and price target

$118 −13.03% close 16.10.26 · market cap $6.1B · General · Medical - Diagnostics & Research IWM 0.19%
Price targets and ratings of

Analyst consensus

Moderate Buy

5 Buy4 Hold0 Sell

Ratings of 9 analysts in the last 3 months · top analysts only

12-month forecast

$130+10.3% upside

Based on 9 price targets given in the last 3 months, the average target is $130, the highest $180, the lowest $56.00. The average is +10.3% from the last price of $118.

$50.00$100$150Jan 26AprJulOctJan 27AprJulOctHigh$180Average$130Low$56.00
Highest target $180 Average target $130 Lowest target $56.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% Morgan Stanley $60.00 → $120+100.0% Hold +1.9% Reiterated 13.10.26on TipRanks 08:55 +2.2%next day +0.6%
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $88.00 → $180+104.5% Buy +52.8% Reiterated 13.10.26on TipRanks 08:41 +2.2%next day +0.6%
Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% Morgan Stanley $120 Hold +1.9% Reiterated 12.10.26on TipRanks 09:00 −2.2%next day +2.2%
Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% Goldman Sachs $75.00 → $120+60.0% Hold +1.9% Reiterated 05.10.26on TipRanks 07:40 +6.9%next day −11.5% · 5 days −11.3%
Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% Wolfe Research $105 → $175+66.7% Buy +48.5% Reiterated 02.10.26on TipRanks 09:50 +7.3%next day +6.9% · 5 days −3.0%
Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% Guggenheim $75.00 → $155+106.7% Buy +31.6% Reiterated 01.10.26on TipRanks 08:35 −5.6%next day +7.3% · 5 days −1.3%
Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% Canaccord Genuity $80.00 → $150+87.5% Buy +27.3% Reiterated 28.09.26on TipRanks Sep 27 23:30 +5.3%next day +3.2% · 5 days +15.0%
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $88.00 Buy −25.3% Reiterated 24.09.26on TipRanks 09:25 +15.5%next day +0.8% · 5 days +6.3%
Robert Bamberger Robert W. Baird $86.00 → $118+37.2% Buy +0.2% Reiterated 22.09.26on TipRanks 07:25 +0.5%next day +0.7% · 5 days +27.0%
Bradley Bowers★★★★★★★★★★#1314 · hits 90% · avg +72.1% Mizuho Securities — Buy — Reiterated 22.09.26on TipRanks 07:20 +0.5%next day +0.7% · 5 days +27.0%
Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% RBC Capital $84.00 Hold −28.7% Reiterated 21.09.26on TipRanks Sep 23 21:45 +32.1%next day +0.5% · 5 days +23.9%
Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% Morgan Stanley $60.00 Hold −49.1% Reiterated 21.09.26on TipRanks Sep 22 06:45 +32.1%next day +0.5% · 5 days +23.9%
Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% Goldman Sachs $60.00 → $75.00+25.0% Hold −36.3% Reiterated 20.09.26on TipRanks Sep 21 08:15 +32.1%next day +0.5% · 5 days +23.9%
Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% Wolfe Research $105 Buy −10.9% Initiated 13.09.26on TipRanks Sep 14 09:30 −0.5%next day +0.9% · 5 days +41.0%
David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% Piper Sandler $56.00 Hold −52.5% Reiterated 06.08.26on TipRanks 07:45 −14.4%next day +9.0% · 5 days +6.4%
Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% Guggenheim $75.00 Buy −36.3% Reiterated 05.08.26on TipRanks Aug 6 06:55 +2.2%next day −14.4% · 5 days −7.4%
Paige Chamberlain‏★★★★★★★★★★#7338 · hits 100% · avg +13.9% Wolfe Research — Hold — Initiated 01.06.26on TipRanks Jun 2 03:05 −10.4%next day −7.1% · 5 days −1.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering GRAIL Inc

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
1 year Kyle Mikson CFA★★★★★★★★★★Canaccord Genuity · #2814
Hits 38%127 of 332 Average return +5.9%
2 years Kyle Mikson CFA★★★★★★★★★★Canaccord Genuity · #2814
Hits 38%127 of 332 Average return +5.9%

Most profitable

3 months Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
1 year Kyle Mikson CFA★★★★★★★★★★Canaccord Genuity · #2814
Hits 38%127 of 332 Average return +5.9%
2 years Kyle Mikson CFA★★★★★★★★★★Canaccord Genuity · #2814
Hits 38%127 of 332 Average return +5.9%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $99.00 at a price of $140 (−29.3%); now: $129 at $118 (+9.2%).

$75.00$100$125$150Sep 15Oct 1Oct 15Top analysts$130Average target$129Price$118

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0102041Oct 2571Nov71Dec72Jan 26145Feb554Mar525Apr474May76Jun85Jul64Aug128Sep1410Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy400000
Buy77861214
Hold4654810
Sell000000

Earnings and sales forecast

Next report: 18.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-2.50 (from $-3.22 to $-1.61). Last quarter: $-2.56.

Sales

Next quarter’s sales estimate — $44M (from $42M to $47M). Last quarter: $45M.

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About GRAIL Inc
  • CEO: Joshua J. Ofman
  • Employees: 910
  • 1525 O’Brien Drive, Menlo Park, CA, 94025, US
  • www.grail.com

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Data from the stock’s TipRanks forecast page, read 16 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗